Contact Us
Drug Search Results
More Filters [+]

SEL-068

Alternative Names: sel-068, sel068, sel 068
Latest Update: 2016-01-07
Latest Update Note: Clinical Trial Update

Product Description

a nicotine vaccine candidate for smoking cessation and relapse prevention

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Selecta Biosciences
Company Location: WATERTOWN MA 02472
Company CEO: Carsten Brunn
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SEL-068

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Tobacco Use Disorder|Smoking Cessation

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
SEL-068/101

P1

Completed

Tobacco Use Disorder|Smoking Cessation

2013-01-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions